Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris

Study Identifier
190168-069
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Study Details

Medical Condition
  • Dermatology - Acne
  • Study Drug
  • AGN-190168 Formulation 1
  • AGN-190168 Formulation 2
  • tazarotene gel 0.1%
  • tazarotene cream 0.1%
  • Phase
    Phase 1
    Sex
    Female & Male
    Age
    12+ years

    Protocol Summary

    This is a safety, tolerability and pharmacokinetics study of AGN-190168 in subjects with acne vulgaris.

    Study Locations

    Location
    Status
    Location
    College Station, Texas, United States
    Status
    Not applicable